OCI Unrealized Holding Gain (Loss) on Securities, Net of Tax
Regeneron Pharmaceuticals OCI Unrealized Holding Gain (Loss) on Securities, Net of Tax decreased by 1026.8% to -$65.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 272.7%, from $38.10M to -$65.80M. Over 2 years (FY 2021 to FY 2025), OCI Unrealized Holding Gain (Loss) on Securities, Net of Tax shows an upward trend with a 21.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Reflects the net impact of market movements on the company's book value and overall financial position.
Detailed definition
The change in fair value of investment securities held in the portfolio, net of applicable tax effects. This provides a...
Peer comparison
Standard metric for reporting the impact of market value changes on equity in insurance financial statements.
ms_oci_unrealized_holding_gain_loss_securities_net_of_taxHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$800.00K | -$6.40M | -$35.90M | -$144.90M | -$53.70M | -$51.30M | $57.20M | -$15.70M | $21.30M | $95.40M | $3.50M | $7.90M | $128.20M | $38.10M | $22.10M | $15.70M | $7.10M | -$65.80M |
| QoQ Change | — | -700.0% | -460.9% | -303.6% | +62.9% | +4.5% | +211.5% | -127.4% | +235.7% | +347.9% | -96.3% | +125.7% | >999% | -70.3% | -42.0% | -29.0% | -54.8% | <-999% |
| YoY Change | — | — | — | — | <-999% | -701.6% | +139.5% | +70.8% | +141.5% | — | -93.9% | +150.3% | +501.9% | +988.6% | +179.7% | -87.8% | — | -272.7% |
OCI Unrealized Holding Gain (Loss) on Securities, Net of Tax at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's oci unrealized holding gain (loss) on securities, net of tax?
- Regeneron Pharmaceuticals (REGN) reported oci unrealized holding gain (loss) on securities, net of tax of -$65.80M in Q1 2026.
- How has Regeneron Pharmaceuticals's oci unrealized holding gain (loss) on securities, net of tax changed year-over-year?
- Regeneron Pharmaceuticals's oci unrealized holding gain (loss) on securities, net of tax decreased by 272.7% year-over-year, from $38.10M to -$65.80M.
- What is the long-term trend for Regeneron Pharmaceuticals's oci unrealized holding gain (loss) on securities, net of tax?
- Over 2 years (2021 to 2025), Regeneron Pharmaceuticals's oci unrealized holding gain (loss) on securities, net of tax has grown at a 21.3% compound annual growth rate (CAGR), from -$56.40M to $83.00M.
- What does oci unrealized holding gain (loss) on securities, net of tax mean?
- The after-tax change in the value of investment holdings that have not been sold.